Medicare's Cannabis (CBD) Coverage Plan Sparks Federal Controversy-Is CMS Circumventing FDA Drug Approval Standards?

WASHINGTON, DC / ACCESS Newswire / March 24, 2026 / A new federal initiative allowing up to $500 annually in hemp-derived cannabinoid products for Medicare beneficiaries is raising urgent questions ...
USA Today

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health’s Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with ...

SAN FRANCISCO, CA / ACCESS Newswire / September 30, 2025 / Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company’s novel ...
Applied Clinical Trials Online

Four FDA Actions Reshaping Drug Development in 2026

Early 2026 has brought a series of consequential regulatory moves from the FDA, each reflecting a common thread: the agency ...

Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial Readouts

Denali Therapeutics (NASDAQ:DNLI) founder and CEO Ryan Watts said 2026 is shaping up to be a pivotal year for the company as ...
The Indianapolis Star

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health’s Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with ...

The two programs are being conducted under separate Single-Patient Investigational New Drug (sIND) applications in the United States SAN FRANCISCO, CA / ACCESS Newswire / September 30, 2025 / Jaguar ...